Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Mar 2026 for Lyell Immunopharma, Inc., €10.8M.
Insider track record
Disclosed buys
1
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
ARCH Venture Fund XIII, L.P.: trading record in brief
ARCH Venture Fund XIII, L.P. has a single filing on record, published on 9 March 2026: an open-market purchase of €10.8M in Lyell Immunopharma, Inc. One trade is not enough to describe a pattern. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to ARCH Venture Fund XIII, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations0 total
▲
Same trade as the filing by ARCH Venture Partners IX, LLC, counted once
12M USD22SEC
488,090 shares@ US$25.61100.0% of flowCommon StockSEC:0001012975-26-000234:0
Canonical exit: 4 Jun 2026 (T+90)
1 of 0 declarations
